NCT04916795View on ClinicalTrials.gov

A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Single Dose Vupanorsen In Healthy Chinese Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 17, 2021

Primary Completion Date

October 19, 2021

Study Completion Date

October 19, 2021

Conditions
Healthy
Interventions
DRUG

Vupanorsen

80 mg subcutaneous injection

DRUG

Vupanorsen

80 mg subcutaneous injection

Trial Locations (1)

201107

Huashan Hospital,Fudan University, Shanghai

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04916795 - A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Single Dose Vupanorsen In Healthy Chinese Adults | Biotech Hunter | Biotech Hunter